Search

Your search keyword '"Palapattu, Ganesh S"' showing total 687 results
Start Over Author "Palapattu, Ganesh S"
687 results on '"Palapattu, Ganesh S"'

1. Integrative multi-region molecular profiling of primary prostate cancer in men with synchronous lymph node metastasis

Author

Singhal, Udit, Nallandhighal, Srinivas, Tosoian, Jeffrey J., Hu, Kevin, Pham, Trinh M., Stangl-Kremser, Judith, Liu, Chia-Jen, Karim, Razeen, Plouffe, Komal R., Morgan, Todd M., Cieslik, Marcin, Lucianò, Roberta, Shariat, Shahrokh F., Finocchio, Nadia, Dambrosio, Lucia, Doglioni, Claudio, Chinnaiyan, Arul M., Tomlins, Scott A., Briganti, Alberto, Palapattu, Ganesh S., Udager, Aaron M., and Salami, Simpa S.

Published
2024
Full Text
View/download PDF

5. Everolimus Exposure as a Predictor of Toxicity in Renal Cell Cancer Patients in the Adjuvant Setting: Results of a Pharmacokinetic Analysis for SWOG S0931 (EVEREST), a Phase III Study (NCT01120249).

Author

Synold, Timothy W, Plets, Melissa, Tangen, Catherine M, Heath, Elisabeth I, Palapattu, Ganesh S, Mack, Philip C, Stein, Mark N, Meng, Maxwell V, Lara, Primo, Vogelzang, Nicholas J, Thompson, Ian Murchie, and Ryan, Christopher W

Subjects
Renal cell carcinoma, adjuvant chemotherapy, everolimus, pharmacokinetics, therapeutic drug monitoring
Abstract

BackgroundS0931 is assessing recurrence-free survival in renal cell carcinoma (RCC) patients randomized to receive everolimus (EVE) versus placebo for one year following nephrectomy. Due to a higher than expected dropout rate, we assessed EVE trough levels in the adjuvant setting to evaluate the relationship between EVE exposure and probability of toxicity.MethodsPatients received 10 mg daily EVE for nine 6-week cycles. Pre-dose whole blood samples were collected pre-cycle 2 and pre-cycle 3 and analyzed for EVE. Patients with pre-cycle 2 and/or pre-cycle 3 EVE results were used in the analysis. Patients were segregated into quartiles (Q) based on EVE levels and logistic regression was used to model the most common adverse event outcomes using EVE trough as a predictor. Hazard and odds ratios were adjusted for age, BMI and performance status.ResultsA total of 467 patients were included in this analysis. Quartiles normalized to an EVE dose of 10 mg/day were  22.8 ng/mL, respectively. EVE trough levels increased with increasing age (p

Published
2019

6. Development of a Whole-urine, Multiplexed, Next-generation RNA-sequencing Assay for Early Detection of Aggressive Prostate Cancer

Author

Cani, Andi K., Hu, Kevin, Liu, Chia-Jen, Siddiqui, Javed, Zheng, Yingye, Han, Sumin, Nallandhighal, Srinivas, Hovelson, Daniel H., Xiao, Lanbo, Pham, Trinh, Eyrich, Nicholas W., Zheng, Heng, Vince, Randy, Jr, Tosoian, Jeffrey J., Palapattu, Ganesh S., Morgan, Todd M., Wei, John T., Udager, Aaron M., Chinnaiyan, Arul M., Tomlins, Scott A., and Salami, Simpa S.

Published
2022
Full Text
View/download PDF

7. Urinary MyProstateScore (MPS) to Rule out Clinically-Significant Cancer in Men with Equivocal (PI-RADS 3) Multiparametric MRI: Addressing an Unmet Clinical Need

Author

Tosoian, Jeffrey J., Singhal, Udit, Davenport, Matthew S., Wei, John T., Montgomery, Jeffrey S., George, Arvin K., Salami, Simpa S., Mukundi, Stanley G., Siddiqui, Javed, Kunju, Lakshmi P., Tooke, Benjamin P., Ryder, C. Yoonhee, Dugan, Sarah P., Chopra, Zoey, Botbyl, Rachel, Feng, Yilin, Sessine, Michael S., Eyrich, Nicholas W., Ross, Ashley E., Trock, Bruce J., Tomlins, Scott A., Palapattu, Ganesh S., Chinnaiyan, Arul M., Niknafs, Yashar S., and Morgan, Todd M.

Published
2022
Full Text
View/download PDF

8. Molecular Characterization of Clear Cell Renal Cell Carcinoma Reveals Prognostic Significance of Epithelial-mesenchymal Transition Gene Expression Signature

Author

Nallandhighal, Srinivas, Vince, Randy, Karim, Razeen, Groves, Skylar, Stangl-Kremser, Judith, Russell, Christopher, Hu, Kevin, Pham, Trinh, Cani, Andi K., Liu, Chia-Jen, Zaslavsky, Alexander, Mehra, Rohit, Cieslik, Marcin, Morgan, Todd M., Palapattu, Ganesh S., Udager, Aaron M., and Salami, Simpa S.

Published
2022
Full Text
View/download PDF

9. Multigene profiling of CTCs in mCRPC identifies a clinically relevant prognostic signature

Author

Singhal, Udit, Wang, Yugang, Henderson, James, Niknafs, Yashar S, Qiao, Yuanyuan, Gursky, Amy, Zaslavsky, Alexander, Chung, Jae-Seung, Smith, David C, Karnes, R Jeffrey, Chang, S Laura, Feng, Felix Y, Palapattu, Ganesh S, Taichman, Russell S, Chinnaiyan, Arul M, Tomlins, Scott A, and Morgan, Todd M

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Human Genome, Cancer, Biotechnology, Prostate Cancer, Clinical Research, Urologic Diseases, Genetics, 4.1 Discovery and preclinical testing of markers and technologies, Detection, screening and diagnosis, Good Health and Well Being, Aged, Biomarkers, Tumor, Cell Line, Tumor, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, Humans, Liquid Biopsy, Male, Middle Aged, Multiplex Polymerase Chain Reaction, Neoplasm Metastasis, Neoplastic Cells, Circulating, Nomograms, Oncogene Proteins, Fusion, Precision Medicine, Prognosis, Prostatic Neoplasms, Castration-Resistant, RNA, Long Noncoding, Receptors, Androgen, Survival Analysis, Wnt Signaling Pathway, Developmental Biology, Oncology & Carcinogenesis, Biochemistry and cell biology, Oncology and carcinogenesis
Abstract

The trend toward precision-based therapeutic approaches dictated by molecular alterations offers substantial promise for men with metastatic castration-resistant prostate cancer (mCRPC). However, current approaches for molecular characterization are primarily tissue based, necessitating serial biopsies to understand changes over time and are limited by the challenges inherent to extracting genomic material from predominantly bone metastases. Therefore, a circulating tumor cell (CTC)-based assay was developed to determine gene expression across a panel of clinically relevant and potentially actionable prostate cancer-related genes. CTCs were isolated from the whole blood of mCRPC patients (n = 41) and multiplex qPCR was performed to evaluate expression of prostate cancer-related target genes (n = 78). A large fraction of patients (27/41, 66%) had detectable CTCs. Increased androgen receptor (AR) expression (70% of samples) and evidence of Wnt signaling (67% of samples) were observed. The TMPRSS2:ERG fusion was expressed in 41% of samples, and the aggressive prostate cancer-associated long noncoding RNA SChLAP1 was upregulated in 70%. WNT5a [HR 3.62, 95% confidence interval (CI), 1.63-8.05, P = 0.002], AURKA (HR 5.56, 95% CI, 1.79-17.20, P = 0.003), and BMP7 (HR 3.86, 95% CI, 1.60-9.32, P = 0.003) were independently predictive of overall survival (FDR < 10%) after adjusting for a panel of previously established prognostic variables in mCRPC (Halabi nomogram). A model including Halabi, WNT5a, and AURKA expression, termed the miCTC score, outperformed the Halabi nomogram alone (AUC = 0.89 vs. AUC = 0.70). Understanding the molecular landscape of CTCs has utility in predicting clinical outcomes in patients with aggressive prostate cancer and provides an additional tool in the arsenal of precision-based therapeutic approaches in oncology.Implications: Analysis of CTC gene expression reveals a clinically prognostic "liquid biopsy" signature in patients with metastatic castrate-resistance prostate cancer. Mol Cancer Res; 16(4); 643-54. ©2018 AACR.

Published
2018

12. Serial Molecular Profiling of Low-grade Prostate Cancer to Assess Tumor Upgrading: A Longitudinal Cohort Study

Author

Salami, Simpa S., Tosoian, Jeffrey J., Nallandhighal, Srinivas, Jones, Tonye A., Jr, Brockman, Scott, Elkhoury, Fuad F., Bazzi, Selena, Plouffe, Komal R., Siddiqui, Javed, Liu, Chia-Jen, Kunju, Lakshmi P., Morgan, Todd M., Natarajan, Shyam, Boonstra, Philip S., Sumida, Lauren, Tomlins, Scott A., Udager, Aaron M., Sisk, Anthony E., Jr, Marks, Leonard S., and Palapattu, Ganesh S.

Published
2021
Full Text
View/download PDF

13. Antisense oligonucleotides and nucleic acids generate hypersensitive platelets

Author

Zaslavsky, Alexander, Adams, Mackenzie, Cao, Xiu, Yamaguchi, Adriana, Henderson, James, Busch-Østergren, Peter, Udager, Aaron, Pitchiaya, Sethuramasundaram, Tourdot, Benjamin, Kasputis, Tadas, Church, Samuel J., Lee, Samantha K., Ohl, Sydney, Patel, Shivam, Morgan, Todd M., Alva, Ajjai, Wakefield, Thomas W., Reichert, Zachery, Holinstat, Michael, and Palapattu, Ganesh S.

Published
2021
Full Text
View/download PDF

14. Molecular Profiling to Determine Clonality of Serial Magnetic Resonance Imaging/Ultrasound Fusion Biopsies from Men on Active Surveillance for Low-Risk Prostate Cancer

Author

Palapattu, Ganesh S, Salami, Simpa S, Cani, Andi K, Hovelson, Daniel H, de la Vega, Lorena Lazo, Vandenberg, Kelly R, Bratley, Jarred V, Liu, Chia-Jen, Kunju, Lakshmi P, Montgomery, Jeffery S, Morgan, Todd M, Natarajan, Shyam, Huang, Jiaoti, Tomlins, Scott A, and Marks, Leonard S

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Genetics, Prostate Cancer, Urologic Diseases, Clinical Research, Cancer, Biomedical Imaging, Aging, Biotechnology, Aetiology, Detection, screening and diagnosis, 2.1 Biological and endogenous factors, 4.1 Discovery and preclinical testing of markers and technologies, Good Health and Well Being, Aged, Biopsy, Clonal Evolution, High-Throughput Nucleotide Sequencing, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Mutation, Neoplasm Grading, Neoplasm Proteins, Prostatic Neoplasms, Ultrasonography, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

Purpose: To determine whether MRI/ultrasound (MRI/US) fusion biopsy facilitates longitudinal resampling of the same clonal focus of prostate cancer and to determine whether high-grade cancers can evolve from low-grade clones.Experimental Design: All men on active surveillance who underwent tracking MRI/US fusion biopsy of Gleason 6 prostate cancer, on at least two distinct occasions, between 2012 and 2014 were enrolled. MRI/US fusion was used to track and resample specific cancer foci. IHC for ERG and targeted RNA/DNA next-generation sequencing (NGS) were performed on formalin-fixed paraffin-embedded prostate biopsy specimens to assess clonality.Results: Thirty-one men with median age and PSA of 65 years and 4.6 ng/mL, respectively, were analyzed. The median sampling interval was 12 months (range, 5-35). Of the 26 evaluable men, ERG IHC concordance was found between initial and repeat biopsies in 25 (96%), indicating resampling of the same clonal focus over time. Targeted NGS supported ERG IHC results and identified unique and shared driving mutations, such as IDH1 and SPOP, in paired specimens. Of the nine men (34.6%) who were found to have Gleason ≥7 on repeat biopsy, all displayed temporal ERG concordance. Prioritized genetic alterations were detected in 50% (13/26) of paired samples. Oncogenic mutations were detected in 22% (2/9) of Gleason 6 cancers prior to progression and 44% (4/9) of Gleason ≥7 cancers when progression occurred.Conclusions: Precise tracking of prostate cancer foci via MRI/US fusion biopsy allowed subsequent resampling of the same clonal focus of cancer over time. Further research is needed to clarify the grade progression potential of Gleason 6 prostate cancer. Clin Cancer Res; 23(4); 985-91. ©2016 AACR.

Published
2017

15. Detection of Germline Variants in Patients With Localized and Metastatic Prostate Cancer Through Guideline-Based Testing.

Author

Abusamra, Sophia M., Solorzano, Marissa A., Quarles, Jake, Luke, Mallory, Patel, Milan, Vince Jr, Randy, Jiang, Ralph, Volin, Joshua, Jacobs, Michelle F., Kaffenberger, Samuel D., Salami, Simpa S., Palmbos, Phillip, Caram, Megan E. V., Hollenbeck, Brent K., Palapattu, Ganesh S., Merajver, Sofia D., Stoffel, Elena M., Hafron, Jason, Morgan, Todd M., and Reichert, Zachery R.

Published
2025
Full Text
View/download PDF

20. Analysis of the Tumor Immune Microenvironment (TIME) in Clear Cell Renal Cell Carcinoma (ccRCC) Reveals an M0 Macrophage-Enriched Subtype: An Exploration of Prognostic and Biological Characteristics of This Immune Phenotype

Author

Farha, Mark, primary, Nallandhighal, Srinivas, additional, Vince, Randy, additional, Cotta, Brittney, additional, Stangl-Kremser, Judith, additional, Triner, Daniel, additional, Morgan, Todd M., additional, Palapattu, Ganesh S., additional, Cieslik, Marcin, additional, Vaishampayan, Ulka, additional, Udager, Aaron M., additional, and Salami, Simpa S., additional

Published
2023
Full Text
View/download PDF

21. Intermediate Endpoints After Postprostatectomy Radiotherapy: 5-Year Distant Metastasis to Predict Overall Survival

Author

Jackson, William C., Suresh, Krithika, Tumati, Vasu, Allen, Steven G., Dess, Robert T., Salami, Simpa S., George, Arvin, Kaffenberger, Samuel D., Miller, David C., Hearn, Jason W.D., Jolly, Shruti, Mehra, Rohit, Hollenbeck, Brent K., Palapattu, Ganesh S., Schipper, Matthew, Feng, Felix Y., Morgan, Todd M., Desai, Neil B., and Spratt, Daniel E.

Published
2018
Full Text
View/download PDF

23. De novo neuroendocrine transdifferentiation in primary prostate cancer–a phenotype associated with advanced clinico-pathologic features and aggressive outcome

Author

Abdulfatah, Eman, Reichert, Zachery R., Davenport, Matthew S., Chinnaiyan, Arul M., Dadhania, Vipulkumar, Wang, Xiaoming, Mannan, Rahul, Kunju, Lakshmi P., Hollenbeck, Brent K., Montgomery, Jeffrey S., Kaffenberger, Samuel D., Morgan, Todd M., Alva, Ajjai S., Palapattu, Ganesh S., Vaishampayan, Ulka N., Alumkal, Joshi J., Spratt, Daniel E., Udager, Aaron M., and Mehra, Rohit

Published
2021
Full Text
View/download PDF

25. Comparing Patient-reported Functional Outcomes After Radical Prostatectomy in Historical and Contemporary Practice

Author

Singhal, Udit, primary, Hollenbeck, Brent K., additional, Kaffenberger, Samuel D., additional, Salami, Simpa S., additional, George, Arvin K., additional, Skolarus, Ted A., additional, Montgomery, Jeffrey S., additional, Wittmann, Daniela A., additional, Miller, David C., additional, Wei, John T., additional, Palapattu, Ganesh S., additional, Montie, James E., additional, Dunn, Rodney L., additional, and Morgan, Todd M., additional

Published
2023
Full Text
View/download PDF

26. Programmed Death-ligand 1 Expression in Upper Tract Urothelial Carcinoma

Author

Skala, Stephanie L., Liu, Tzu-Ying, Udager, Aaron M., Weizer, Alon Z., Montgomery, Jeffrey S., Palapattu, Ganesh S., Siddiqui, Javed, Cao, Xuhong, Fields, Kristina, Abugharib, Ahmed E., Soliman, Moaaz, Hafez, Khaled S., Miller, David, Lee, Cheryl T., Alva, Ajjai, Chinnaiyan, Arul M., Morgan, Todd M., Spratt, Daniel E., Jiang, Hui, and Mehra, Rohit

Published
2017
Full Text
View/download PDF

31. Development and Validation of MyProstateScore 2.0 to Detect Clinically Significant Prostate Cancer

Author

Tosoian, Jeffrey J., primary, Zhang, Yuping, additional, Xiao, Lanbo, additional, Xie, Cassie, additional, Samora, Nathan L., additional, Niknafs, Yashar S., additional, Chopra, Zoey, additional, Siddiqui, Javed, additional, Zheng, Heng, additional, Herron, Grace, additional, Vaishampayan, Neil, additional, Arivoli, Kumaran, additional, Trock, Bruce J., additional, Ross, Ashley E., additional, Morgan, Todd M., additional, Palapattu, Ganesh S., additional, Salami, Simpa S., additional, Kunju, Lakshmi P., additional, Zheng, Yingye, additional, Wei, John T., additional, and Chinnaiyan, Arul M., additional

Published
2023
Full Text
View/download PDF

32. Data from Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature

Author

Singhal, Udit, primary, Wang, Yugang, primary, Henderson, James, primary, Niknafs, Yashar S., primary, Qiao, Yuanyuan, primary, Gursky, Amy, primary, Zaslavsky, Alexander, primary, Chung, Jae-Seung, primary, Smith, David C., primary, Karnes, R. Jeffrey, primary, Chang, S. Laura, primary, Feng, Felix Y., primary, Palapattu, Ganesh S., primary, Taichman, Russell S., primary, Chinnaiyan, Arul M., primary, Tomlins, Scott A., primary, and Morgan, Todd M., primary

Published
2023
Full Text
View/download PDF

33. Supplementary Figures S1 - S6, Tables S1 - S2 from Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature

Author

Singhal, Udit, primary, Wang, Yugang, primary, Henderson, James, primary, Niknafs, Yashar S., primary, Qiao, Yuanyuan, primary, Gursky, Amy, primary, Zaslavsky, Alexander, primary, Chung, Jae-Seung, primary, Smith, David C., primary, Karnes, R. Jeffrey, primary, Chang, S. Laura, primary, Feng, Felix Y., primary, Palapattu, Ganesh S., primary, Taichman, Russell S., primary, Chinnaiyan, Arul M., primary, Tomlins, Scott A., primary, and Morgan, Todd M., primary

Published
2023
Full Text
View/download PDF

41. Supplementary material from Molecular Profiling to Determine Clonality of Serial Magnetic Resonance Imaging/Ultrasound Fusion Biopsies from Men on Active Surveillance for Low-Risk Prostate Cancer

Author

Palapattu, Ganesh S., primary, Salami, Simpa S., primary, Cani, Andi K., primary, Hovelson, Daniel H., primary, Lazo de la Vega, Lorena, primary, Vandenberg, Kelly R., primary, Bratley, Jarred V., primary, Liu, Chia-Jen, primary, Kunju, Lakshmi P., primary, Montgomery, Jeffery S., primary, Morgan, Todd M., primary, Natarajan, Shyam, primary, Huang, Jiaoti, primary, Tomlins, Scott A., primary, and Marks, Leonard S., primary

Published
2023
Full Text
View/download PDF

42. Data from Metabolomic Profiling Reveals Potential Markers and Bioprocesses Altered in Bladder Cancer Progression

Author

Putluri, Nagireddy, primary, Shojaie, Ali, primary, Vasu, Vihas T., primary, Vareed, Shaiju K., primary, Nalluri, Srilatha, primary, Putluri, Vasanta, primary, Thangjam, Gagan Singh, primary, Panzitt, Katrin, primary, Tallman, Christopher T., primary, Butler, Charles, primary, Sana, Theodore R., primary, Fischer, Steven M., primary, Sica, Gabriel, primary, Brat, Daniel J., primary, Shi, Huidong, primary, Palapattu, Ganesh S., primary, Lotan, Yair, primary, Weizer, Alon Z., primary, Terris, Martha K., primary, Shariat, Shahrokh F., primary, Michailidis, George, primary, and Sreekumar, Arun, primary

Published
2023
Full Text
View/download PDF

43. Supplementary Methods, Figures 1-5, Tables 1-11 from Metabolomic Profiling Reveals Potential Markers and Bioprocesses Altered in Bladder Cancer Progression

Author

Putluri, Nagireddy, primary, Shojaie, Ali, primary, Vasu, Vihas T., primary, Vareed, Shaiju K., primary, Nalluri, Srilatha, primary, Putluri, Vasanta, primary, Thangjam, Gagan Singh, primary, Panzitt, Katrin, primary, Tallman, Christopher T., primary, Butler, Charles, primary, Sana, Theodore R., primary, Fischer, Steven M., primary, Sica, Gabriel, primary, Brat, Daniel J., primary, Shi, Huidong, primary, Palapattu, Ganesh S., primary, Lotan, Yair, primary, Weizer, Alon Z., primary, Terris, Martha K., primary, Shariat, Shahrokh F., primary, Michailidis, George, primary, and Sreekumar, Arun, primary

Published
2023
Full Text
View/download PDF

45. Impact of tertiary Gleason pattern 5 on prostate cancer aggressiveness: Lessons from a contemporary single institution radical prostatectomy series

Author

Koloff, Zachary B., Hamstra, Daniel A., Wei, John T., Montgomery, Jeffrey S., Tomlins, Scott A., Wu, Angela J., Morgan, Todd M., Siddiqui, Javed, Paich, Kellie, Chinnaiyan, Arul M., Feng, Felix Y., Weizer, Alon Z., Kunju, Lakshmi P., Hollenbeck, Brent K., Miller, David C., Palapattu, Ganesh S., and Mehra, Rohit

Published
2015
Full Text
View/download PDF

46. Reporting standards for the imaging-based diagnosis of renal masses on CT and MRI: a national survey of academic abdominal radiologists and urologists

Author

Davenport, Matthew S., Hu, Eric M., Smith, Andrew D., Chandarana, Hersh, Hafez, Khaled, Palapattu, Ganesh S., Stuart Wolf, Jr., J., Silverman, Stuart G., Davenport, Matthew, Chandarana, Hersh, Silverman, Stuart, Israel, Gary, Leyendecker, John, Vikram, Raghu, Raman, Steve, Remer, Erick, Smith, Andrew, Wang, Jane, and For the Society of Abdominal Radiology Disease Focused Panel on Renal Cell Carcinoma

Published
2017
Full Text
View/download PDF

47. MyProstateScore in men considering repeat biopsy: validation of a simple testing approach

Author

Tosoian, Jeffrey J., primary, Sessine, Michael S., additional, Trock, Bruce J., additional, Ross, Ashley E., additional, Xie, Cassie, additional, Zheng, Yingye, additional, Samora, Nathan L., additional, Siddiqui, Javed, additional, Niknafs, Yashar, additional, Chopra, Zoey, additional, Tomlins, Scott, additional, Kunju, Lakshmi P., additional, Palapattu, Ganesh S., additional, Morgan, Todd M., additional, Wei, John T., additional, Salami, Simpa S., additional, and Chinnaiyan, Arul M., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results